Literature DB >> 12023264

Management of the older person with atrial fibrillation.

Wilbert S Aronow1.   

Abstract

Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to slow immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and with symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds that are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and should be continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in older persons, ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiarrhythmic drugs. Digoxin should not be used to treat patients with paroxysmal AF. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should receive 325 mg of aspirin daily.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023264     DOI: 10.1093/gerona/57.6.m352

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  6 in total

1.  Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019.

Authors:  Gilson Soares Feitosa-Filho; José Maria Peixoto; José Elias Soares Pinheiro; Abrahão Afiune Neto; Afonso Luiz Tavares de Albuquerque; Álvaro César Cattani; Amit Nussbacher; Ana Amelia Camarano; Angela Hermínia Sichinels; Antonio Carlos Sobral Sousa; Aristóteles Comte de Alencar Filho; Claudia F Gravina; Dario Celestino Sobral Filho; Eduardo Pitthan; Elisa Franco de Assis Costa; Elizabeth da Rosa Duarte; Elizabete Viana de Freitas; Emilio Hideyuki Moriguchi; Evandro Tinoco Mesquita; Fábio Fernandes; Gilson Soares Feitosa; Humberto Pierre; Ilnei Pereira Filho; Izo Helber; Jairo Lins Borges; Jéssica Myrian de Amorim Garcia; José Antonio Gordillo de Souza; José Carlos da Costa Zanon; Josmar de Castro Alves; Kalil Lays Mohallem; Laura Mariana de Siqueira Mendonça Chaves; Lídia Ana Zytynski Moura; Márcia Cristina Amélia da Silva; Maria Alice de Vilhena Toledo; Maria Elisa Lucena Sales de Melo Assunção; Mauricio Wajngarten; Mauro José Oliveira Gonçalves; Neuza Helena Moreira Lopes; Nezilour Lobato Rodrigues; Paulo Roberto Pereira Toscano; Pedro Rousseff; Ricardo Antonio Rosado Maia; Roberto Alexandre Franken; Roberto Dischinger Miranda; Roberto Gamarski; Ronaldo Fernandes Rosa; Silvio Carlos de Moraes Santos; Siulmara Cristina Galera; Stela Maris da Silva Grespan; Teresa Cristina Rogerio da Silva; William Antonio de Magalhães Esteves
Journal:  Arq Bras Cardiol       Date:  2019-06-06       Impact factor: 2.000

Review 2.  Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends.

Authors:  Suraj Kapa; Rupa Bala
Journal:  J Atr Fibrillation       Date:  2011-07-15

3.  Pacing for the suppression of paroxysmal atrial fibrillation in an 87-year-old patient.

Authors:  Paul A Levine; Robin Wachsner; Adel El-Bialy
Journal:  Indian Pacing Electrophysiol J       Date:  2003-04-01

Review 4.  Adverse reactions of Amiodarone.

Authors:  Ruben Ml Colunga Biancatelli; Viviana Congedo; Leonardo Calvosa; Marco Ciacciarelli; Alessandro Polidoro; Luigi Iuliano
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

5.  Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea.

Authors:  Min Kim; Woojin Kim; Changsoo Kim; Boyoung Joung
Journal:  Yonsei Med J       Date:  2019-12       Impact factor: 2.759

Review 6.  The evaluation of left ventricular diastolic dysfunction in patients with non-hemorrhagic stroke and atrial fibrillation.

Authors:  Mahdi Najafi-Dalui; Hasan Shemirani; Reyhaneh Zavar; Ali Eghbal
Journal:  ARYA Atheroscler       Date:  2017-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.